Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677451 · ClinicalTrials.gov registry record · Phase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
A Phase 3 study of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05677451 is a Phase 3 study of Chronic Spontaneous Urticaria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 100 participants, below the 1,422-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT05677451, a Phase 3 study of Chronic Spontaneous Urticaria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment
Conditions Studied
Interventions
- DRUG placebo
- DRUG LOU064 (blinded)
Study Locations (20)
Buenos Aires
- Novartis Investigative Site - CABA
- Novartis Investigative Site - CABA
- Novartis Investigative Site - CABA
California
- Kern Research - Bakersfield
- Allergy and Asthma Medical Group and Research Center - San Diego
Florida
- Pediatric Dermatology of Miami at the Pediatric CoE - Coral Gables
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Endeavor Health - Glenview
Kentucky
- Allergy and Asthma Specialist P S C - Owensboro
Ohio
- Toledo Institute of Clinical Research - Toledo
Oklahoma
- Allergy Asthma and Clinical Research - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2032-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05677451
The ClinicalTrials.gov registry entry for NCT05677451 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,422-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT05677451 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Buenos Aires, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05677451 about?
NCT05677451 is a clinical study titled "24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up". The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and toler...
What is the current status of trial NCT05677451?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-07-11. Estimated completion is 2032-03-30.
What conditions does trial NCT05677451 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
What interventions are being tested in trial NCT05677451?
The interventions under investigation include: placebo (DRUG), LOU064 (blinded) (DRUG).
Who is sponsoring clinical trial NCT05677451?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05677451 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
RECRUITING · Phase 3
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
ACTIVE NOT RECRUITING · Phase 3
-
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
ACTIVE NOT RECRUITING · Phase 3
-
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
COMPLETED · Phase 3
-
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.